NovaBay Pharmaceuticals
NBY • AMEX
NovaBay Pharmaceuticals is a biotechnology company in the healthcare sector trading on AMEX, led by CEO Michael Kazley, with a market cap of $94.9M.
CEOMichael Kazley
Market Cap$94.9M
Biotechnology
Healthcare
Employees26.0
Websitenovabay.com
Country
United States of America
Next Earnings
Upcoming earnings announcement for NovaBay Pharmaceuticals
Date
Wednesday, April 1, 2026 (in 2 months)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q4 2025
EPS Estimate
-$0.08
Earnings History
Past 12 earnings reports for NovaBay Pharmaceuticals
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Nov 7, 2025 | Q3 2025 | -$0.23Est: -$0.08 | -187.5% | $521.0K | — |  10-Q |
| Aug 14, 2025 | Q2 2025 | -$0.34Est: -$0.08 | -325.0% | - | — | 10-Q |
| May 15, 2025 | Q1 2025 | -$0.61Est: -$0.24 | -154.2% | -Est: $3.0M | -100.0% | 10-Q |
| Apr 2, 2025 | Q4 2024 | —Est: -$0.24 | — | —Est: $3.0M | — | 10-K |
| Nov 7, 2024 | Q3 2024 | -$0.60Est: -$0.30 | -100.0% | $2.4MEst: $2.6M | -6.9% | 10-Q |
| Aug 13, 2024 | Q2 2024 | -$1.37Est: -$1.23 | -11.4% | $2.4MEst: $3.2M | -23.8% | 10-Q |
| May 9, 2024 | Q1 2024 | -$4.90Est: -$5.25 | +6.7% | $2.6MEst: $3.3M | -19.8% | 10-Q |
| Mar 26, 2024 | Q4 2023 | -$7.35Est: -$10.50 | +30.0% | $3.7MEst: $3.4M | +9.6% | 10-K/A |
| Nov 9, 2023 | Q3 2023 | -$12.95Est: -$14.00 | +7.5% | $3.3MEst: $3.6M | -8.0% | — |
| Aug 10, 2023 | Q2 2023 | -$44.45Est: -$19.25 | -130.9% | $4.6MEst: $3.7M | +25.6% | 10-Q |
| May 11, 2023 | Q1 2023 | -$29.75Est: -$31.85 | +6.6% | $3.1MEst: $3.2M | -2.4% | — |
| Mar 30, 2023 | Q4 2022 | -$51.45Est: -$5.95 | -764.7% | $3.6MEst: $5.1M | -28.6% | — |